Comparison of Five-day Helicobacter Pylori Eradication Regimens: Rabeprazole-based and Omeprazole-based Regimens with and Without Omeprazole Pretreatment

Overview

Journal Curr Ther Res Clin Exp

Specialty Pharmacology

Date 2014 Jun 20

PMID 24944392

Citations 3

Authors

Kyoichi Adachi

Tomoyuki Hashimoto

Shunji Ishihara

Hirofumi Fujishiro

Shuichi Sato

Hiroshi Sato

Yuji Amano

Shuzo Hattori

Yoshikazu Kinoshita

Affiliations

Soon will be listed here.

Abstract

Background: The onset of antisecretory activity of rabeprazole is faster than that of omeprazole.

Objective: This study was performed to compare the efficacy of short-term rabeprazole-based triple therapy with that of omeprazole-based triple therapy and to determine the influence of omeprazole pretreatment in omeprazole-based short-term triple therapy.

Methods: This was a 2-center, open-label, prospective, randomized study. Patients who tested positive for Helicobacter (formerly Campylobacter) pylori were randomized to one of three 5-day regimens: (1) rabeprazole 20 mg BID, amoxicillin 500 mg TID, and clarithromycin 400 mg BID (RAC group); (2) omeprazole 20 mg BID, amoxicillin 500 mg TID, and clarithromycin 400 mg BID without omeprazole pretreatment (OAC1 group); and (3) omeprazole 20 mg BID, amoxicillin 500 mg TID, and clarithromycin 400 mg BID with 5 days of omeprazole pretreatment 20 mg BID (OAC2 group). Eradication was assessed by (13)C-urea breath test and rapid urease test ∼1 month after completion of treatment. All patients who entered this study were included in the intent-to-treat (ITT) analysis, patients who completed the study were included in the per-protocol (PP) analysis, and patients who did not undergo the (13)C-urea breath test and rapid urease test were included in the all-patients-treated (APT) analysis.

Results: A total of 120 patients (86 men, 34 women; mean [SD] age, 55.8 [14.3] years; range, 19-86 years) were assigned to the RAC, OAC1, or OAC2 group (40 patients in each group). ITT, PP, and APT eradication rates in the RAC group were 90%, 92%, and 90%, respectively; in the OAC1 group, 75%, 83%, and 75%; and in the OAC2 group, 85%, 90%, and 87%. These eradication rates were not significantly different between groups.

Conclusions: Eradication rates did not differ significantly between the three 5-day proton pump inhibitor-based triple therapies in this study population. However, 5-day rabeprazole-based triple therapy tends to be more effective than 5-day omeprazole-based triple therapy in the eradication of H pylori, and treatment with omeprazole before eradication therapy may improve the eradication rates of 5-day omeprazole-based therapy.

Citing Articles

Potassium-Competitive Acid Blocker and Proton Pump Inhibitor-Based Regimens for First-Line Eradication: A Network Meta-Analysis.

Malfertheiner P, Moss S, Daniele P, Pelletier C, Jacob R, Tremblay G Gastro Hep Adv. 2024; 1(5):824-834.

PMID: 39131848 PMC: 11307524. DOI: 10.1016/j.gastha.2022.06.009.

Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of infection.

Moss S, Chey W, Daniele P, Pelletier C, Jacob R, Tremblay G Therap Adv Gastroenterol. 2023; 16:17562848231167284.

PMID: 37388121 PMC: 10302680. DOI: 10.1177/17562848231167284.

Influence of pretreatment with H2 receptor antagonists on the cure rates of Helicobacter pylori eradication.

Tokoro C, Inamori M, Koide T, Sekino Y, Iida H, Sakamoto Y Med Sci Monit. 2011; 17(5):CR235-40.

PMID: 21525804 PMC: 3539594. DOI: 10.12659/msm.881762.

References

Sachs G, Shin J, Munson K, Vagin O, Lambrecht N, Scott D . Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000; 14(11):1383-401. DOI: 10.1046/j.1365-2036.2000.00837.x. View

Miwa H, Ohkura R, Nagahara A, Murai T, Ogihara T, Watanabe S . [13C]-urea breath test for assessment of cure of Helicobacter pylori infection at 1 month after treatment. J Clin Gastroenterol. 1999; 27 Suppl 1:S150-3. DOI: 10.1097/00004836-199800001-00024. View

Williams M, Pounder R . Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther. 1999; 13 Suppl 3:3-10. DOI: 10.1046/j.1365-2036.1999.00019.x. View

Gardner J, Perdomo C, Sloan S, Hahne W, Barth J, Rodriguez-Stanley S . Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther. 2002; 16(3):455-64. DOI: 10.1046/j.1365-2036.2002.01158.x. View

Grayson M, Eliopoulos G, Ferraro M, Moellering Jr R . Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1989; 8(10):888-9. DOI: 10.1007/BF01963775. View

Wong B, Wong W, Yee Y, Hung W, Yip A, Szeto M . Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2001; 15(12):1959-65. DOI: 10.1046/j.1365-2036.2001.01118.x. View

Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T . Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther. 2002; 16(10):1811-7. DOI: 10.1046/j.1365-2036.2002.01348.x. View

Adachi K, Fujishiro H, Mihara T, Komazawa Y, Kinoshita Y . Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol. 2003; 18(2):168-71. DOI: 10.1046/j.1440-1746.2003.02922.x. View

Lind T, van Zanten S, Unge P, Spiller R, Bayerdorffer E, OMorain C . Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1996; 1(3):138-44. DOI: 10.1111/j.1523-5378.1996.tb00027.x. View

10.

Trevisani L, Sartori S, Caselli M, Ruina M, Verdianelli G, Abbasciano V . A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. Am J Gastroenterol. 1998; 93(3):390-3. DOI: 10.1111/j.1572-0241.1998.00390.x. View

11.

Parsonnet J, Friedman G, Vandersteen D, Chang Y, Vogelman J, ORENTREICH N . Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325(16):1127-31. DOI: 10.1056/NEJM199110173251603. View

12.

Lind T, Megraud F, Unge P, Bayerdorffer E, OMorain C, Spiller R . The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology. 1999; 116(2):248-53. DOI: 10.1016/s0016-5085(99)70119-8. View

13.

Tsuchiya M, Imamura L, Park J, KOBASHI K . Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull. 1995; 18(8):1053-6. DOI: 10.1248/bpb.18.1053. View

14.

Isaacson P, Spencer J . Is gastric lymphoma an infectious disease?. Hum Pathol. 1993; 24(6):569-70. DOI: 10.1016/0046-8177(93)90233-7. View

15.

Pounder R . New developments in Helicobacter pylori eradication therapy. Scand J Gastroenterol Suppl. 1997; 223:43-5. View

16.

Marshall B, Warren J . Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1(8390):1311-5. DOI: 10.1016/s0140-6736(84)91816-6. View

17.

Adamek R, Szymanski C, Pfaffenbach B . Pantoprazole suppresses Helicobacter pylori without affecting cure. Helicobacter. 1999; 4(4):266-71. DOI: 10.1046/j.1523-5378.1999.99991.x. View

18.

Ohara T, Goshi S, Taneike I, Tamura Y, Zhang H, Yamamoto T . Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter. 2001; 6(2):125-9. DOI: 10.1046/j.1523-5378.2001.00018.x. View

19.

Hunt R . pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol. 1993; 88(4):481-3. View

20.

Labenz J, Leverkus F, Borsch G . Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol. 1994; 29(12):1070-5. DOI: 10.3109/00365529409094890. View